The effectiveness of teriflunomide in patients with multiple sclerosis in China: a real-world comparison to no DMT treatment in the first year after diagnosis.
Bitao BuChao QuanWenyu LiQiuming ZengZiyan ShiBo ChenLei ZhouLuya JinHongyu ZhouHuan YangPublished in: Therapeutic advances in neurological disorders (2023)
Teriflunomide is associated with a lower relapse rate and less disability accumulation in Chinese patients with multiple sclerosis.